Receptor for advanced glycation end products and its ligands: Initiators or amplifiers of joint inflammation - A bit of both?

Arthritis and Rheumatism

Volumn 54, Issue 1, 2006, Pages 14-18

  Moser, Bernhard ^a   Herold, Kevan C ^a   Schmidt, Ann Marie ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN;

CARTILAGE CELL; CARTILAGE DEGENERATION; EDITORIAL; INFLAMMATION; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; ARTHRITIS; HUMANS; LIGANDS; RECEPTORS, IMMUNOLOGIC;

EID: 31044433372     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21522     Document Type: Editorial

References (22)

1. Steenvoorden MM, Huizinga TW, Verzijl N, Bank RA, Ronday HK, Luning HA, et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006;54: 267-77.
2. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006;54:111-8.
3. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005;15:16R-28R.
4. ε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274:31740-9.
5. ε- carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:488-92.
6. ε- (carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-13.
7. ε- (carboxymethyl) lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003;52:2137-43.
8. Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I. Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 1999;19:35-7.
9. Drinda S, Franke S, Ruster M, Petrow P, Pullig O, Stein G, et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 2005;25:411-3.
10. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999;97: 889-901.
11. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
12. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002;46: 2598-603.
13. Andersson U, Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. J Intern Med 2004;255:344-50.
14. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004;50:1286-95.
15. Youssef P, Roth J, Frosch M, Costello P, Fitzgerald O, Sorg C, et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP 8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999;26:2523-8.
16. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35.
17. Kokkola R, Li J, Sundberg E, Aveberger AC, Palmblad K, Yang H, et al. Successful targeting of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48:2052-8.
18. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003;9:287-93.
19. Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, et al. Blockade of the late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 2004;173:1399-405.
20. Dumitriu IE, Baruah P, Valentinins B, Voll RE, Merrmann M, Nawroth PP, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation endproducts. J Immunol 2005;174:7506-15.
21. Prevost G, Fajardy I, Fontaine P, Danze PM, Besmond C. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 1999; 26:343-8.
22. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation endproducts in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005;7:R817-24.